Vol 27, No 4 (2020)
Published online: 2020-09-10

open access

Page views 1193
Article views/downloads 1458
Get Citation

Connect on Social Media

Connect on Social Media

ISCHEMIA trial: The long-awaited evidence to confirm our prejudices

Carlos Cortés1, Thomas W. Johnson2, Sigmund Silber3, Piotr P. Buszman4, Tudor C. Poerner5, Francesco Lavarra6, Borja Ibáñez789, Yongcheol Kim10, Karl Mischke11, Miłosz Jaguszewski12, Juan Luis Gutiérrez-Chico13
Pubmed: 32929701
Cardiol J 2020;27(4):336-341.


Not available

Article available in PDF format

View PDF Download PDF file


  1. Maron D, Hochman J, Reynolds H, et al. Initial Invasive or Conservative Strategy for Stable Coronary Disease. N Engl J Med. 2020; 382(15): 1395–1407.
  2. Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020; 41: 407–477.
  3. Machiavelli, Niccolò, 1469-1527. The prince. Reprinted with revisions 1984. Harmondsworth, Eng.; New York, NY: Penguin Books; 1981.Available at: https://search.library.wisc.edu/catalog/999715970702121.
  4. Maron DJ, Hochman JS, O'Brien SM, et al. ISCHEMIA Trial Research Group. International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial: Rationale and design. Am Heart J. 2018; 201: 124–135.
  5. Hochman JS, Reynolds HR, Bangalore S, et al. ISCHEMIA Research Group. Baseline Characteristics and Risk Profiles of Participants in the ISCHEMIA Randomized Clinical Trial. JAMA Cardiol. 2019; 4(3): 273–286.
  6. Spertus JA, Jones PG, Maron DJ, et al. ISCHEMIA Research Group. Health-Status Outcomes with Invasive or Conservative Care in Coronary Disease. N Engl J Med. 2020; 382(15): 1408–1419.
  7. Gutiérrez-Chico JL, Louvard Y. DECISION-CTO: A "negative" clinical trial? Really? Cardiol J. 2017; 24(3): 231–233.
  8. Bangalore S, Maron D, Stone G, et al. Routine revascularization versus initial medical therapy for stable ischemic heart disease: a systematic review and meta-analysis of randomized trials. Circulation. 2020.
  9. Werner GS, Martin-Yuste V, Hildick-Smith D, et al. EUROCTO trial investigators. A randomized multicentre trial to compare revascularization with optimal medical therapy for the treatment of chronic total coronary occlusions. Eur Heart J. 2018; 39(26): 2484–2493.
  10. Lee SW, Lee PH, Ahn JM, et al. Randomized trial evaluating percutaneous coronary intervention for the treatment of chronic total occlusion. Circulation. 2019; 139(14): 1674–1683.
  11. Toth GG, Toth B, Johnson NP, et al. Revascularization decisions in patients with stable angina and intermediate lesions: results of the international survey on interventional strategy. Circ Cardiovasc Interv. 2014; 7(6): 751–759.
  12. Tonino PAL, De Bruyne B, Pijls NHJ, et al. FAME Study Investigators. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med. 2009; 360(3): 213–224.
  13. Neumann F-J, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019; 40: 87–165.
  14. De Bruyne B, Pijls NHJ, Kalesan B, et al. FAME 2 Trial Investigators. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med. 2012; 367(11): 991–1001.
  15. Jaguszewski M, Zabalza Cerdeiriña M, Alushi B, et al. How should I treat recurrent chest pain and systolic dysfunction after chemotherapy with anthracyclines? EuroIntervention. 2017; 12(13): 1674–1677.
  16. Gutiérrez-Chico JL, Zhao S, Chatzizisis YS. Vorticity: At the crossroads of coronary biomechanics and physiology. Atherosclerosis. 2018; 273: 115–116.
  17. Boden WE, O’Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007; 356: 1503–1516.
  18. Härle T, Zeymer U, Hochadel M, et al. Real-world use of fractional flow reserve in Germany: results of the prospective ALKK coronary angiography and PCI registry. Clin Res Cardiol. 2017; 106(2): 140–150.
  19. Lee HS, Lee JM, Nam CW, et al. Consensus document for invasive coronary physiologic assessment in Asia-Pacific countries. Cardiol J. 2019; 26(3): 215–225.
  20. Sleight P. Debate: Subgroup analyses in clinical trials: fun to look at - but don’t believe them! Curr Control Trials Cardiovasc Med. 2000; 1(1): 25–27.
  21. Figulla HR, Lauten A, Maier LS, et al. Percutaneous Coronary Intervention in Stable Coronary Heart Disease -Is Less More? Dtsch Arztebl Int. 2020; 117(9): 137–144.
  22. Gutiérrez-Chico JL, Chen Y, Yu W, et al. Diagnostic accuracy and reproducibility of optical flow ratio for functional evaluation of coronary stenosis in a prospective series. Cardiol J. 2020 [Epub ahead of print].